Core Viewpoint - The company provided a detailed report on the usage and management of raised funds from its initial public offering, highlighting the total amount raised, expenses incurred, and the allocation of funds to various projects [1][2]. Fundraising Overview - The company raised a total of RMB 379.4 million by issuing 20 million shares at RMB 18.97 each, with net proceeds amounting to RMB 344 million after deducting issuance costs of RMB 35.4 million [1]. - As of June 30, 2025, the total amount of raised funds used was RMB 189.97 million, with a remaining balance of RMB 28.27 million [2][5]. Fund Management - The company established a dedicated fund management system in compliance with relevant laws and regulations, including a tripartite supervision agreement with banks to ensure proper storage and usage of the raised funds [1][2]. - The balance of the raised funds in dedicated bank accounts was RMB 27.31 million in demand deposits and RMB 28 million in structured deposits as of June 30, 2025 [2][7]. Project Funding and Usage - The company allocated funds to two main projects: the construction of a 4,000-ton high-grade powder metallurgy component project and a technology renovation project for powder metallurgy new materials, with a total investment of RMB 243.31 million [5][6]. - As of June 30, 2025, the company had used RMB 148.30 million for the first project and RMB 25.43 million for the second project, resulting in a total surplus of RMB 89.75 million from both projects [6][7]. Surplus Fund Management - The company decided to permanently supplement its working capital with the surplus funds from the completed projects, totaling RMB 89.75 million, and planned to close the related dedicated fund accounts [6][7]. - The company has also utilized idle raised funds for cash management, generating a return of RMB 22.92 million from investments in safe and liquid financial products [2][6]. Compliance and Reporting - The company confirmed that all disclosures regarding the usage of raised funds were timely, accurate, and complete, adhering to the regulatory requirements set by the Shenzhen Stock Exchange [8].

Group 1 - The company reported a total of RMB 75,880.00 million raised from its initial public offering (IPO) with a net amount of RMB 68,955.19 million after deducting issuance costs [5][32] - As of June 30, 2025, the company has utilized RMB 1,587.80 million from the IPO funds directly for investment projects and earned RMB 957.73 million in net interest and investment income [3][4] - The remaining balance of the IPO funds is RMB 25,001.86 million, which includes RMB 6,001.86 million in the special account and RMB 19,000.00 million in idle funds [3][4] Group 2 - In 2023, the company raised RMB 18,830.26 million through a targeted issuance of shares, with a net amount of RMB 18,342.53 million after deducting issuance costs [5][33] - By June 30, 2025, the company has used RMB 2,568.79 million from the targeted issuance for investment projects and earned RMB 173.77 million in net interest and investment income [5][6] - The remaining balance from the targeted issuance is RMB 6,651.10 million, including RMB 3,651.10 million in the special account and RMB 3,000.00 million in idle funds [5][6] Group 3 - The company has established a management system for the raised funds to ensure compliance with relevant regulations and to enhance the efficiency of fund usage [6][8] - The company has signed tripartite supervision agreements with its underwriters and banks to regulate the responsibilities and obligations of all parties involved in the management of the raised funds [7][10] - The company has not experienced any significant changes in its operational status or any major events that would impact its financial situation during the reporting period [3][12] Group 4 - The company plans to use up to RMB 23,000 million of temporarily idle raised funds for cash management, ensuring that it does not affect the progress of investment projects [31][39] - The cash management will involve investing in safe, liquid, and guaranteed-return financial products, including structured deposits and certificates of deposit [39][41] - The company has received no objections from its underwriter regarding the cash management plan, confirming that it complies with relevant regulations [47][48]

证券代码：300158 证券简称：振东制药 公告编号：2025-044 山西振东制药股份有限公司 一、董事会会议召开情况 山西振东制药股份有限公司（以下简称"公司"）第六届董事会第 四次会议于 2025 年 8 月 22 日上午 9:00 在公司会议室通过现场及通 讯表决方式召开，会议通知于 2025 年 8 月 12 日以电话、邮件等方式 通知全体董事。会议应出席董事 9 名，实际出席董事 9 名。会议由公 司董事长李昆先生主持，公司全体监事及高级管理人员列席了会议。 本次会议的出席人数、召集、召开程序和议事内容均符合国家有关法 律、法规及《公司章程》的规定。 二、董事会会议审议情况 年半年度报告>及其摘要》。 《2025 年半年度报告》及《2025 年半年度报告摘要》内容详见 中国证监会创业板指定信息披露网站。 本议案已由董事会审计委员会审议并通过。 及其子公司使用自有资金进行现金管理的议案》。 本着股东利益最大化原则，为提高资金的使用效率，在确保不影 响公司正常经营以及保证流动性和资金安全的前提下，公司董事会同 意公司及公司子公司使用额度不超过人民币 10 亿元的自有资金进行 现金管理，并授权管理层在上 ...

Group 1 - The sixth meeting of the supervisory board of Shanxi Zhendong Pharmaceutical Co., Ltd. was held on August 22, 2025, with all three supervisors present, confirming compliance with legal and regulatory requirements [1] - The supervisory board reviewed the 2025 semi-annual report and found that the report accurately reflects the company's actual situation without any false statements or omissions [1] - The semi-annual report and its summary are available on the designated information disclosure website of the China Securities Regulatory Commission [1] Group 2 - The supervisory board approved the proposal for the company and its subsidiaries to use up to RMB 1 billion of idle self-owned funds for cash management, focusing on low to medium-risk financial products [2] - The decision to utilize idle funds is aimed at improving capital efficiency and cash management returns, aligning with the interests of the company and all shareholders, particularly minority shareholders [2] - The cash management proposal complies with relevant regulations and does not involve high-risk investment products as defined by the Shenzhen Stock Exchange [2]

证券代码：300143 证券简称：盈康生命 公告编号：2025-038 盈康生命科技股份有限公司 第六届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 盈康生命科技股份有限公司（以下简称"公司"）于 2025 年 8 月 12 日以电话、 邮件等方式向全体董事发出召开公司第六届董事会第二十次会议的通知。会议于 场结合通讯的方式召开。会议应出席董事 9 人，实出席董事 9 人，董事谭丽霞、马 安捷以现场方式出席会议并投票表决，董事黄雯瑶、龚雯雯、潘绵顺、沈旭东、独 立董事杜媛、独立董事姜峰、独立董事陈晓满以通讯方式出席会议并投票表决。本 次会议由董事长谭丽霞女士主持，公司的高级管理人员列席了会议。 本次会议的通知、召集、召开和表决程序符合《中华人民共和国公司法》等有 关法律、行政法规、部门规章、规范性文件及《盈康生命科技股份有限公司公司章 程》的规定。 二、董事会会议审议情况 （一）审议通过《关于公司<2025 年半年度报告>及其摘要的议案》 具体内容详见公司同日于巨潮资讯网（http://www.cninfo ...

Core Viewpoint - Shanxi Zhendong Pharmaceutical Co., Ltd. has announced the use of its own funds for cash management, with a maximum investment of RMB 1 billion, aimed at improving fund utilization efficiency while ensuring normal operations and liquidity [1][2]. Group 1: Cash Management Details - The purpose of the investment is to enhance fund utilization efficiency without affecting normal operations and ensuring fund safety [2]. - The company plans to invest in low to medium-risk financial products issued by banks, securities firms, trust companies, and asset management companies, excluding high-risk investment types [2]. - The resolution is valid for one year from the date of approval by the board [2]. - The management is authorized to implement the cash management within the specified limit [2]. Group 2: Risk Management Measures - The company will adhere to prudent investment principles, selecting low to medium-risk investment products, with the finance department monitoring progress and addressing risks promptly [3]. - The supervisory department will audit and supervise the use and custody of funds for investment products, estimating potential returns and losses [3]. - The supervisory board has the authority to oversee the use of funds and may hire professional institutions for auditing if necessary [3]. Group 3: Board and Supervisory Approval - The proposal received approval from both the board and the supervisory board, which deemed it beneficial for improving fund utilization efficiency and cash management returns, aligning with the interests of the company and all shareholders [3].

Group 1 - The company, Zhendong Pharmaceutical, announced on August 24 that its sixth board meeting was held on August 22, 2025, where it reviewed the proposal for cash management using its own funds [1] - For the year 2024, Zhendong Pharmaceutical's revenue composition is as follows: 77.86% from pharmaceutical production and sales, 21.34% from medicinal herb planting, and 0.79% from other businesses [1] - As of the report date, Zhendong Pharmaceutical has a market capitalization of 8.4 billion yuan [1]

Core Viewpoint - The recent developments regarding Chendian International (郴电国际) indicate a positive trend in its financial performance, alongside significant corporate governance changes, including the cancellation of the supervisory board and revisions to company regulations [1][2][3]. Financial Performance - As of the mid-2025 report, Chendian International reported a main revenue of 1.957 billion yuan, a year-on-year increase of 1.26% [1] - The net profit attributable to shareholders reached 25.916 million yuan, reflecting a year-on-year growth of 29.55% [1] - The net profit after deducting non-recurring gains and losses was 4.494 million yuan, up 130.54% year-on-year [1] - In Q2 2025, the company achieved a single-quarter main revenue of 956 million yuan, a 2.58% increase year-on-year [1] - The single-quarter net profit attributable to shareholders was 15.068 million yuan, a decline of 21.66% year-on-year [1] - The debt ratio stood at 71.83%, with investment income of 312.734 million yuan and financial expenses of 116 million yuan, resulting in a gross profit margin of 8.18% [1] Shareholder Changes - As of June 30, 2025, the number of shareholders increased by 27.04% to 25,200 [1][5] - The average number of shares held per shareholder decreased from 18,600 to 14,700, with an average holding value of 104,700 yuan [1] Corporate Governance Changes - On August 20, 2025, the company announced the cancellation of the supervisory board, with its powers transferred to the audit committee of the board of directors, pending shareholder approval [2] - The company also approved revisions to several internal regulations, which will be submitted for shareholder review [3] Investment and Financial Management - The company plans to use up to 500 million yuan of its own funds to purchase principal-protected financial products, a decision already approved by the board [4] - A subsidiary, Hunan Deneng Xiangjiang Hydropower Co., plans to invest 15.3831 million yuan in an ecological power station project, with an expected annual power generation of 11.5 million kWh [4] Upcoming Meetings - Chendian International will hold its first extraordinary general meeting of 2025 on September 10, 2025, to discuss the cancellation of the supervisory board and other governance matters [6]

Core Viewpoint - Nasda Co., Ltd. plans to utilize up to 2 billion RMB of idle self-owned funds for cash management to enhance fund efficiency while ensuring operational needs are met [1][3]. Cash Management Plan - The company and its subsidiaries will invest in low-risk, high-security, and liquid cash management products issued by banks and securities firms, including structured deposits and wealth management products [1]. - The maximum amount of idle funds to be used for cash management is capped at 2 billion RMB within a 12-month period, with the funds being able to roll over within this limit [1]. Risk Control Measures - A dedicated working group will be established to oversee cash management activities, adhering to internal approval processes outlined in the company's charter [2]. - The company will implement strict investment principles, real-time analysis of product value changes, and regular audits to monitor fund usage and security [2]. Impact on Company Operations - The cash management initiative is expected to improve fund efficiency and generate returns for the company and its shareholders without affecting daily operations or core business activities [3]. - The board of directors and supervisory board have expressed support for the cash management plan, emphasizing its alignment with shareholder interests and compliance with necessary procedures [3].

Core Viewpoint - Zhuzhou CRRC Times Electric Co., Ltd. plans to utilize idle self-owned funds for cash management to enhance fund efficiency and maximize shareholder value [1][2]. Group 1: Cash Management Overview - The company intends to invest up to RMB 1,500,000 million or equivalent foreign currency in cash management products, which include structured deposits, large certificates of deposit, time deposits, and notice deposits [2]. - The investment will be made from idle self-owned funds of the company or its wholly-owned and controlling subsidiaries, and the funds can be used cyclically within a 12-month period from the board's approval [2]. - The board has authorized the chairman or designated personnel to make investment decisions and sign relevant documents, with the finance center responsible for implementation [2]. Group 2: Risk Control Measures - The company acknowledges potential systemic risks due to macroeconomic influences and will adhere to prudent investment principles when selecting investment targets, focusing on reputable and large banks [3]. - The company will monitor the cash management products' performance and take necessary protective measures if potential risks are identified [3]. Group 3: Impact on Daily Operations - The investment in cash management products will not affect the company's normal operations and is aimed at generating investment returns to enhance overall performance and provide better returns for shareholders [4].